Oncology firm OnKure raises $55M
BOULDER — OnKure Inc., a Boulder-based developer of cancer treatments, has raised $55 million in its Series B round.
In a statement, the company said the investment will be used to advance its current pipeline of early-stage and pre-clinical oncology treatments.
The latest round dwarfs OnKure’s prior Series A-1 investment, which amounted to $3.26 million.
As part of their firm’s investments, Acorn Bioventures partner Issac Manke and Cormorant Asset Management managing director Andrew Phillips will join OnKure’s board. That brings the company’s board size from four to six.
“I am grateful for the financial and strategic support from our new investors that will…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
BOULDER — Even with the COVID-10 pandemic several years in the rearview mirror, it remains…
-
Boulder Community Health this month became the first facility in Colorado to offer patients a…
-
LOVELAND — The Stinging Nettle has taken up residence in downtown, filling a hole recently…
-
Nextera Healthcare LLC and ImagineMD have combined to form a single direct-primary-care organization for employer…
